PM
Could have something to do with this approval this year for Mylan Dapto and being placed under their label as per a prev recent POH Ann.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205037
I am assuming if our agreement has strict requirements re a generic Dapto being approved and sold then it could imply that mylan have not adhered to developing a TPM Dapto as per agreement opting to produce generic first against terms of agreement.
Hence why POH indicate they have to weigh up their options on that as a breach maybe.
PMCould have something to do with this approval this year for...
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
